Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. - Wikidata - wikimedia - TriplyDB

Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration.

Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration.

http://www.wikidata.org/entity/Q43500228

about

Antihypertensive agents for preventing diabetic kidney disease Interplay of vitamin D, erythropoiesis, and the renin-angiotensin system Perspectives on systems biology applications in diabetic kidney disease Measurement of renal function in patients with chronic kidney disease Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis Present and future in the treatment of diabetic kidney disease Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy Acoustic radiation force impulse imaging for noninvasive evaluation of renal parenchyma elasticity: preliminary findings Renal recovery Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis Label Free Detection of Sensitive Mid-Infrared Biomarkers of Glomerulonephritis in Urine Using Fourier Transform Infrared Spectroscopy.Non-invited review: prevention of microvascular diabetic complications by fenofibrate: lessons from FIELD and ACCORD.Associations of dietary fat with albuminuria and kidney dysfunction.Renal protection in diabetes: lessons from ONTARGET.Kidney function, albuminuria, and all-cause mortality in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) study.Impact of age and overt proteinuria on outcomes of stage 3 to 5 chronic kidney disease in a referred cohort.The use of targeted biomarkers for chronic kidney disease.Effect of vitamin-D analogue on albuminuria in patients with non-dialysed chronic kidney disease stage 4-5: a retrospective single center study.End organ damage in hypertension.Antiproteinuric effect of add-on paricalcitol in CKD patients under maximal tolerated inhibition of renin-angiotensin system: a prospective observational study.Dual renin-angiotensin-aldosterone system blockade for diabetic kidney disease.T/L-type calcium channel blocker reduces the composite ranking of relative risk according to new KDIGO guidelines in patients with chronic kidney disease Early change in proteinuria as a surrogate outcome in kidney disease progression: a systematic review of previous analyses and creation of a patient-level pooled dataset.Changes in albuminuria predict mortality and morbidity in patients with vascular disease initial angiotensin receptor blockade-induced decrease in albuminuria is associated with long-term renal outcome in type 2 diabetic patients with microalbuminuria: a post hoc analysis of the IRMA-2 trial.Albuminuria and racial disparities in the risk for ESRD.Is nocturnal blood pressure reduction the secret to reducing the rate of progression of hypertensive chronic kidney disease?Prospective Swiss cohort study of living-kidney donors: study protocol.Diverging association of reduced glomerular filtration rate and albuminuria with coronary and noncoronary events in patients with type 2 diabetes: the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study.Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes.Short-Term High Fat Intake Does Not Significantly Alter Markers of Renal Function or Inflammation in Young Male Sprague-Dawley Rats.Significance of urinary full-length and ectodomain forms of megalin in patients with type 2 diabetes.The renal transcriptome of db/db mice identifies putative urinary biomarker proteins in patients with type 2 diabetes: a pilot study.Incidence of stroke symptoms among adults with chronic kidney disease: results from the REasons for Geographic And Racial Differences in Stroke (REGARDS) study.Understanding the mechanisms of proteinuria: therapeutic implications Urinary matrix metalloproteinase activity in diabetic kidney disease: a potential marker of disease progression.Repeated treatment with bone marrow cell secretory products maintains long-term renoprotection in experimental chronic kidney disease: a placebo-controlled trial.Biomarkers and surrogate endpoints in kidney disease.Rate and determinants of association between advanced retinopathy and chronic kidney disease in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicenter study.Urine podocin:nephrin mRNA ratio (PNR) as a podocyte stress biomarker

P2860

Q24202090-EDAE1C52-0D87-4B02-A668-FA01AFA6D15D Q26822500-457D7003-B03E-49ED-AD65-E1310D178C30 Q26823206-EA907FC3-10EE-4BCD-B757-25E524840BCF Q26853698-3B542FD0-0482-4368-9172-9EE4F74857B6 Q26863404-73DA861B-7E0D-4892-B6C5-F605A4431EB1 Q26864133-888827EB-66AC-4981-BA30-DE13A8E31BEC Q28748796-1972A59E-7F7F-41AF-8201-3FD282B1B483 Q30452095-022A4254-F691-493D-8CD0-30EA744D0EA5 Q33750273-3321D152-1294-4C5B-8084-67EA93517305 Q33805412-290FDDCF-071A-410B-9745-DED6E1AA6525 Q33870550-A180CD2C-6D04-47F5-8C1F-BC9567305587 Q33901914-5E53E4BC-6DA5-4601-B7F9-EE3DE30EC03F Q34119963-143B0037-5BD2-47D6-9BF4-D2DE07D65AF4 Q34221460-6F2D9BD0-A400-4907-A41C-D4CD2DD09268 Q34238467-D4D3056C-BBDA-4FEF-B572-21F214063A97 Q34281450-828A7049-AFB5-423A-BDB1-17D7B6737425 Q34346928-40084D1B-A975-400A-9D0C-689675007357 Q34408823-EFBFE5A0-715D-4D57-B994-93904E31138A Q34444944-0806EA88-D722-46DB-B1F5-9693E7AF5823 Q34483554-5AA2BE68-193D-437E-8584-241123D1C0C4 Q34604473-80636933-22D5-47D3-A972-370D7A43AAB8 Q34788186-9EBECBDD-BB02-4C92-9A22-97CEF8743486 Q35025425-F928BD9D-AD05-4B1E-A173-72124C83D624 Q35108899-F088370B-46CD-428F-8CC6-BB8FC423D2B9 Q35179914-C08A3BD0-377F-4DC8-BCC5-A8A562F28820 Q35210216-BC8A5A36-6295-4706-86DA-BD5176A89AA3 Q35400901-E8A3F3DE-C633-40FA-A762-74AF3AC6F0B0 Q35529711-37E6818D-400B-4884-982A-850B55F0BC49 Q35620125-3A933A49-219D-4B66-A6F1-81561B4BA7F2 Q35721420-E79B7DD4-657E-4CDA-9031-21ED85D92273 Q35817372-2DA9F2E3-B432-4647-BF05-FAD04C4E4149 Q35898292-1C8AFED4-E0F1-4CB8-9089-BB9D2F96D745 Q35924547-F4C700B9-CDB5-4963-AD72-64A6F00BBBE9 Q35953248-94B0269E-F179-4759-8E87-E05637A18625 Q36100123-226B7472-B381-4ADE-956F-9E8CF187286B Q36206158-32F27E8D-FC0C-4365-9DD3-DDB6517CC7CE Q36278420-A1AE78AF-AAE9-4E7A-8633-70636DC1D586 Q36284659-6EF7DBD8-5619-42CE-A10B-395E9950C781 Q36334589-DCE44F73-DA24-4738-ABBB-D936FE07FEF4 Q36389219-720CFA14-1026-4EAD-A902-3F96EC051A3A

P2860

Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration.

http://www.wikidata.org/entity/Q43500228

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Proteinuria as a surrogate out ...... Food and Drug Administration.

@en

Proteinuria as a surrogate out ...... Food and Drug Administration.

@nl

type

label

Proteinuria as a surrogate out ...... Food and Drug Administration.

@en

Proteinuria as a surrogate out ...... Food and Drug Administration.

@nl

prefLabel

Proteinuria as a surrogate out ...... Food and Drug Administration.

@en

Proteinuria as a surrogate out ...... Food and Drug Administration.

@nl

P1433

Q43500228-F5462983-6D41-434B-800E-B3BE16447AD1

P1476

Q43500228-0D7AE6A8-6976-471A-A799-E37D44442278

P2093

Q43500228-2555C73E-FC1C-4875-BB6B-1D42C0E73C47

Q43500228-4C92949B-5271-4611-A489-4666886F8801

Q43500228-674917DF-04F9-4C14-BD45-CDBAB89EC9FE

Q43500228-6BB0D90A-A54A-4BEF-B00E-3E2E06A5AB9A

Q43500228-8927159A-AD93-4EFD-A9D3-6214004F4C84

Q43500228-BAD9B5B8-BB3A-4746-8111-77D08E39FACC

Q43500228-D2839DCA-6A9D-414E-99B7-8D1C08D6D751

Q43500228-F1A45A64-1C5D-41A2-B3F0-72D935D8575D

P304

Q43500228-57C8EDC7-3239-4946-AE34-BD3495109827

P31

Q43500228-C5552010-6EC8-4FD8-A637-6D5BED620C85

P356

Q43500228-2AA1EE9B-E0B2-4A2A-AB76-1D191E6CC5C0

P433

Q43500228-BDC18E36-DC75-40E5-B559-C083730D3294

P478

Q43500228-55522FA8-F79B-48A3-A45D-B5155C7BD5D8

P577

Q43500228-7CC552E6-9E4B-4431-A1C1-039FF7D1CD01

P698

Q43500228-120DFD15-8A9E-4C34-A675-17DB630CCE4B

P921

Q43500228-020EF1D2-19F3-4AE4-9B98-92E38F1EA4B5

P356

J.AJKD.2009.04.029

P1433

American Journal of Kidney Diseases

P1476

Proteinuria as a surrogate out ...... Food and Drug Administration.

@en

P2093

Aaron Friedman

http://www.w3.org/2001/XMLSchema#string

Andrew S Levey

http://www.w3.org/2001/XMLSchema#string

Bertram Kasiske

http://www.w3.org/2001/XMLSchema#string

Daniel Cattran

http://www.w3.org/2001/XMLSchema#string

John Sedor

http://www.w3.org/2001/XMLSchema#string

Katherine Tuttle

http://www.w3.org/2001/XMLSchema#string

Thomas Hostetter

http://www.w3.org/2001/XMLSchema#string

W Greg Miller

http://www.w3.org/2001/XMLSchema#string

P304

205-226

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/J.AJKD.2009.04.029

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P577

2009-07-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19577347

http://www.w3.org/2001/XMLSchema#string

P921